Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Vascular disrupting agents (VDAs) target tumor vasculature but often cause systemic toxicity.
• Developing VDAs with improved safety and efficacy profiles is crucial for clinical application.

Purpose of the Study:

• To design and characterize ICT2588, a novel VDA activated by membrane-type 1 matrix metalloproteinase (MT1-MMP).
• To evaluate the selective activation, antitumor activity, and therapeutic potential of ICT2588 in preclinical models.

Main Methods:

• ICT2588 was designed for MT1-MMP specific activation.
• In vitro chemosensitivity assays were performed using cancer cell lines with and without MT1-MMP expression.
• In vivo studies involved administering ICT2588 to tumor-bearing mice and evaluating tumor vascularization, necrosis, and efficacy.
• Combination therapy with doxorubicin was assessed.

Main Results:

• ICT2588 demonstrated selective activation and cytotoxicity in MT1-MMP expressing cells (HT1080) but not in non-expressing cells (MCF7).
• ICT2588 administration in mice led to active metabolite formation, reduced tumor vasculature, and tumor necrosis.
• ICT2588 showed superior antitumor activity, reduced toxicity, and an improved therapeutic index compared to its active metabolite.
• Combination therapy with doxorubicin significantly enhanced antitumor response and induced complete tumor regressions.

Conclusions:

• ICT2588 is a novel, tumor-specific VDA activated by MT1-MMP, offering a promising therapeutic strategy.
• The improved efficacy and reduced toxicity profile of ICT2588 support its clinical development.
• Targeted VDA activation in the tumor microenvironment represents a viable approach to enhance cancer therapy.